Arrowhead Pharmaceuticals released interim human data showing its RNAi obesity candidates produced meaningful fat loss in small cohorts, including when combined with Lilly’s tirzepatide (Zepbound). Company statements and BioCentury reporting cited reductions in visceral fat, total fat and liver fat and announced plans to advance programs into Phase 2. Arrowhead also signaled broader development and financing plans tied to adipose-targeted RNA delivery. Independent coverage flagged the data as early but potentially competitive in the crowded obesity space, especially as combinations with established GLP-1/GIP agents may amplify outcomes. Arrowhead described the results as proof-of-concept for its delivery platform to adipose tissue, a technical hurdle for RNA therapeutics, and will refine doses and endpoints as it moves into later-stage testing.